|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
This phase I trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the proteasome inhibitor bortezomib when combined with carboplatin in ovarian cancer patients with recurrent and platinum- and taxane-resistant disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
108
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
68-71
|
|
pubmed:meshHeading |
pubmed-meshheading:17905421-Adult,
pubmed-meshheading:17905421-Aged,
pubmed-meshheading:17905421-Aged, 80 and over,
pubmed-meshheading:17905421-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17905421-Boronic Acids,
pubmed-meshheading:17905421-Carboplatin,
pubmed-meshheading:17905421-Dose-Response Relationship, Drug,
pubmed-meshheading:17905421-Female,
pubmed-meshheading:17905421-Humans,
pubmed-meshheading:17905421-Middle Aged,
pubmed-meshheading:17905421-Neoplasm Recurrence, Local,
pubmed-meshheading:17905421-Ovarian Neoplasms,
pubmed-meshheading:17905421-Prospective Studies,
pubmed-meshheading:17905421-Proteasome Endopeptidase Complex,
pubmed-meshheading:17905421-Pyrazines
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
|
|
pubmed:affiliation |
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA. peramire@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
